The corporate-backed health management service raised the cash from Perceptive Advisors and has used $30m to buy musculoskeletal-focused Physera.

Vetmeduni has joined forces with incubator Accent to boost resources for commercialising its veterinary research.

GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.

The rare disease drug developer pulled in $145m through a round led by Pivotal BioVenture Partners and backed by Mitsui and Fidelity.

GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, which has now raised at least $166m to date.

OSI has returned to back Oxford indoor mapping spinout Navenio as the latter expands the market for its hospital workforce allocation system.

Johnson & Johnson Innovation – JJDC was among the investors in an $11.7m round for blood sealant technology developer Gatt Technologies.

John Öhd is to become Karolinska Institute's chief scientific officer on the back of 13 years of biotech industry expertise.

Holmusk, developer of a behavioural healthcare evidence platform, has completed a $21.5m round co-led by corporate venturing unit Optum Ventures.